HAE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HAE is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has some constructive longer-term technical support from bullish moving averages and positive analyst target revisions, but momentum is mixed, there is no clear proprietary buy signal, and short-term trend indicators are still soft. If the investor is impatient and wants to buy now rather than wait, this is still more of a hold than an immediate buy.
Current price is 73.61, below the previous close of 75.07. The trend structure is mixed: SMA_5 > SMA_20 > SMA_200 is bullish and suggests the broader trend remains intact, but MACD histogram is -0.567 and negatively expanding, which points to weakening near-term momentum. RSI_6 at 52.18 is neutral, so the stock is neither oversold nor overbought. Key levels: pivot 75.53, resistance at 78.50 and 80.34, support at 72.56 and 70.72. The probability model also leans mildly negative over the next week and month, which argues against aggressive buying today.
["Mizuho raised its price target to $85 from $70 and kept an Outperform rating.", "The analyst commentary says the IVIG end-market remains healthy.", "NexSys is reportedly performing better than competition.", "Core atrial fibrillation volumes remain robust, supporting the operating backdrop.", "Bullish moving average structure remains intact."]
["No news in the recent week, so there is no fresh catalyst to drive immediate upside.", "MACD is negative and weakening, indicating short-term momentum loss.", "RSI is neutral, so there is no oversold setup to support a quick bounce.", "Model-based stock trend is slightly negative over the next week and month.", "No recent hedge fund, insider, or congress trading signal stands out as bullish.", "No AI Stock Picker or SwingMax signal is present today."]
No usable latest-quarter financial snapshot was provided because the financial data returned an error, so I cannot assess the latest quarter season directly. Based on the available analyst commentary, the company appears to be benefiting from healthy end-market demand and solid competitive performance in NexSys, which suggests the business trend is holding up, but there is not enough reported financial detail here to confirm revenue or earnings acceleration.
Analyst sentiment is mixed but leaning constructive. Recent target changes include Mizuho raising PT to $85 and keeping Outperform, Citi raising PT to $70 but keeping Neutral, Barrington lowering PT to $89 but still Outperform, Baird lowering PT to $67 and keeping Outperform, JPMorgan lowering PT to $62 and keeping Neutral, and BTIG lowering PT to $84 while keeping Buy. The pros view is that core demand and product competitiveness remain solid, supporting upside potential. The cons view is that some firms have trimmed targets due to softer profitability expectations and mixed results, which keeps the street divided rather than outright bullish.
